Psoriasis Archives - Page 2 of 42

Psoriasis and psoriatic arthritis increase cardiovascular risks.

Do TNFis Reduce the Risk for Progression to PsA in Patients With Psoriasis?

By

Heidi W. Moore

June 11, 2020

Researchers evaluated the use of TNFis vs methotrexate in reducing the risk for progression to psoriatic arthritis in patients with psoriasis.

Psoriasis

Management Strategies for Unforeseen Events of Psoriasis Biotech Therapies

By

Brandon May

June 10, 2020

Management strategies for the more commonly encountered events seen in patients with psoriasis treated with biotechnologic therapies are reviewed.

Psoriasis

New, 10-Item Questionnaire Effectively Captures Overall Psoriasis Burden in Adults

By

Emily Pond

June 9, 2020

A novel tool assesses the overall individual psoriasis burden in patients.

Psoriasis

Suboptimal Cardiometabolic Screening Rates for Patients With Psoriasis, Hidradenitis Suppurativa, and Atopic Dermatitis

By

Emily Pond

June 9, 2020

Despite their known associations, patients with psoriasis, hidradenitis suppurativa, and atopic dermatitis are not often screened for cardiometabolic comorbidities.

Psoriasis

Ixekizumab Clears Skin, Nail Psoriasis Better Than Ustekinumab Through 1 Year

By

Brandon May

June 9, 2020

Ixekizumab demonstrated greater ability than ustekinumab to clear both skin and nail psoriasis through 1 year of treatment.

Clinician examining a lower back CT scan

Psoriasis

Integrated Analysis Shows Long-Term Safety, Tolerability of Ixekizumab in Psoriasis, PsA, and axSpA

By

Morgan E. Meissner

June 8, 2020

Researchers evaluated the long-term safety and tolerability of ixekizumab in adults with psoriasis, psoriatic arthritis and axial spondyloarthritis.

Psoriasis

Adalimumab 80 mg Intensified Treatment Safely Improves Psoriasis Severity

By

Brandon May

June 5, 2020

An intensified treatment with adalimumab for psoriasis may allow for a reduction in injections or longer intervals between treatments—improving adherence rates.